SCHEMBL5764475

SCHEMBL5764475

COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3n2S(=O)(=O)c2cc(C(=O)O)ccc2C)c1OC.[Na]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 5/20 0.39
ATP4B P51164 5/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 2/20 0.39
CYP2C9 P11712 1/20 0.39
SLC22A2 O15244 1/20 0.39
DDAH1 O94760 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
ABCB1 P08183 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
ADRA1A P35348 1/20 0.39
FASN P49327 1/20 0.39
SLC47A2 Q86VL8 1/20 0.39
SLC47A1 Q96FL8 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5764451 0.99 ATP4A (0.39) ATP4AATP4BKDM4EHPGDCYP2C9
SCHEMBL5763940 0.94 ATP4A (0.40) ATP4AATP4BKDM4EHPGDCYP2C9
SCHEMBL5763923 0.93 ATP4A (0.40) ATP4AATP4BKDM4EHPGDCYP2C9
SCHEMBL5764460 0.93 ATP4A (0.39) ATP4AATP4BKDM4EHPGDCYP2C9
SCHEMBL5764485 0.89 ATP4A (0.39) ATP4AATP4BKDM4EHPGDCYP2C9
SCHEMBL5760981 0.89 ATP4A (0.35) ATP4AATP4BKDM4EHPGDCYP2C9
SCHEMBL5764467 0.88 ATP4A (0.39) ATP4AATP4BKDM4EHPGDCYP2C9
SCHEMBL5763928 0.88 ATP4A (0.40) ATP4AATP4BKDM4EHPGDCYP2C9
SCHEMBL7007925 0.86 ATP4A (0.43) ATP4AATP4BKDM4EHPGDCYP2C9
SCHEMBL7006711 0.86 ATP4A (0.43) ATP4AATP4BKDM4EHPGDCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556371-B1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR WINSTON PHARMACEUTICALS LLC (US) 2006-04-19 EP disclosed
US-20050182101-A1 Prodrugs of proton pump inhibitors GARST MICHAEL (US) 2005-08-18 US disclosed
US-20050143423-A1 Prodrugs of proton pump inhibitors background of the invention GARST MICHAEL (US) 2005-06-30 US disclosed
US-6897227-B2 Prodrugs of proton pump inhibitors Winston Pharmaceuticals, Inc. (US) 2005-05-24 US disclosed
US-20040102484-A1 Prodrugs of proton pump inhibitors ALEVIUM PHARMACEUTICALS, INC. 2004-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102484-A1 Prodrugs of proton pump inhibitors ABCB11, SLC10A2, SI ATP4A 41/4885ATP4B 61/4885KDM4E 1754/4885
US-20050143423-A1 Prodrugs of proton pump inhibitors background of the invention ABCB11, SLC10A2, SI ATP4A 71/4885ATP4B 90/4885KDM4E 1796/4885
US-20050182101-A1 Prodrugs of proton pump inhibitors ABCB11, SLC10A2, SI ATP4A 38/4885ATP4B 42/4885KDM4E 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.